Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
相关临床试验
256
231 进行中
药物批准
24
批准总数
监管机构
2
监管机构数
成立时间
N/A
进行中（未招募）
208
81.3%
已完成
4
1.6%
尚未招募
23
9.0%
招募中
19
7.4%
Unknown
2
0.8%
- Novartis India Ltd's Board of Directors approved the acquisition of the 'Minipress' and 'Minipres' trademarks from Pfizer Inc. USA and Pfizer Products Inc. USA for approximately ₹1,250 crore. - The transaction covers trademarks registered in India and certain related intellectual property rights, executed through an asset purchase agreement and trademark assignment deeds. - Minipress XL (prazosin) is indicated in India for hypertension and benign prostatic hyperplasia, recording revenue of ₹228.6 crore with a 6.3% CAGR over four years. - Pfizer Ltd will discontinue the marketing, distribution, and sale of Minipress XL following Pfizer Inc USA's decision to discontinue its manufacture.
- The global women's clinical trials and CRO market is projected to grow from $9.9 billion in 2026 to $22.3 billion by 2036, at a CAGR of 8.5%. - Growth is driven by rising prevalence of women-predominant conditions, regulatory requirements for sex-specific safety evaluation, and precision medicine adoption. - Decentralized trial models are accelerating enrollment; Lindus Health's hybrid trials leveraged over 30 million EHRs to double enrollment speed versus traditional approaches. - U.S.-China tariff friction is disrupting biospecimen flows and central lab operations, prompting sponsors to shift recruitment toward CRO networks in India, Southeast Asia, and Europe.
- Innovent Biologics and Pfizer announced a strategic global licensing and collaboration agreement worth up to $10.5 billion to develop 12 promising early-stage cancer medicines. - The partnership combines Innovent's discovery capabilities with Pfizer's global development expertise, focusing on antibody-drug conjugates and multi-specific antibodies with novel payloads. - Under the agreement, Innovent will receive $650 million upfront and up to $9.85 billion in milestone payments, plus double-digit royalties on approved products. - The collaboration includes co-development and co-commercialization opportunities across diverse oncology programs, with Innovent retaining Greater China rights for select programs.
- Marksans Pharma Ltd received final FDA approval for its generic Benzonatate capsules in 100mg and 200mg strengths, bioequivalent to Pfizer's Tessalon Capsules. - The non-narcotic antitussive medication treats persistent cough, bronchitis, pneumonia, and other lung infections by numbing respiratory tract stretch receptors. - Following the regulatory approval announcement, Marksans Pharma shares skyrocketed 9% initially before closing 6.01% higher at Rs 166.32 on NSE. - This approval represents the company's latest FDA success, following previous approval for Loperamide Hydrochloride tablets in November through its wholly-owned subsidiary.
- VST BIO Corporation closed a $45 million Series A financing led by Coefficient Giving to advance its lead stroke therapeutic VB-001 into first-in-human studies in 2026. - VB-001 is a first-in-class monoclonal antibody targeting vascular inflammation and edema in acute ischemic stroke patients, with demonstrated efficacy in preclinical stroke studies. - The company appointed former Pfizer SVP and CSO William Sessa to its Board of Directors to leverage his decades of experience in translating vascular therapeutics from research to clinical trials. - The funding will enable VST BIO to expand its therapeutic platform and build core development capabilities for its preclinical-stage vascular disease programs.
- Recent clinical trial developments in Crohn's disease include positive Phase 2a data for Agomab's ontunisertib in fibrostenosing disease and completion of first cohorts for Onco3R's SIK3 inhibitor O3R-5671. - TREMFYA demonstrates durable remission at two years as the first IL-23 inhibitor with fully subcutaneous treatment regimen, while receiving EC approval for ulcerative colitis maintenance therapy. - Major pharmaceutical companies including AbbVie, Takeda, Johnson & Johnson, and Pfizer continue to drive innovation in Crohn's disease therapeutics through extensive clinical trial programs. - Merck expands its tulisokibart development program with Phase 2b trials in three additional immune-mediated inflammatory diseases, highlighting growing therapeutic options.
- A Geneva University Hospital team won the 2026 Pfizer Prize for developing MVX-ONCO-1, a personalized therapeutic cancer vaccine that combines patient tumor cells with immune-stimulating adjuvants. - The first-in-human Phase I study treated 34 patients with advanced solid tumors resistant to other treatments, with over half showing clinical benefit ranging from disease stabilization to prolonged survival. - The two-pronged approach uses irradiated patient tumor cells as a personalized vaccine while implanting biocompatible capsules that continuously release immune-stimulating factors under the skin. - No significant side effects were observed in the minimally invasive treatment, which involved six injections over nine weeks and represents 15 years of research development.
- AbbVie launched a Phase 1 trial testing ABBV-901 in 207 adults with ovarian cancer, evaluating the experimental intravenous drug both as monotherapy and in combination with bevacizumab. - The company simultaneously initiated a Phase 1 safety study of ABBV-243 in healthy volunteers, using a randomized, double-blind, placebo-controlled design to assess pharmacokinetics and safety. - Both trials represent AbbVie's strategic investment in expanding its oncology pipeline beyond current mature franchises to offset future patent cliff concerns. - The ABBV-901 ovarian cancer program positions AbbVie to compete in a crowded therapeutic space against established players including Roche and AstraZeneca.
- The SOLTI-1303 PATRICIA phase II trial demonstrated that combining palbociclib, trastuzumab, and endocrine therapy significantly improved progression-free survival in previously treated HER2-positive breast cancer patients. - The triplet regimen achieved a hazard ratio of 0.52 for progression-free survival compared to standard care, with 24-month survival rates of 24.0% versus 4.3%. - Despite frequent grade 3 or higher adverse events in 61.5% of patients, primarily neutropenia, no permanent treatment discontinuations occurred due to toxicity. - The study specifically targeted patients with HER2-positive, PAM50 luminal A/B advanced breast cancer, representing a promising new treatment strategy for this subset.
- Pfizer's BRAFTOVI plus MEKTOVI combination therapy demonstrated a median overall survival of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer. - The Phase 2 PHAROS trial showed four-year overall survival rates of 49% for treatment-naïve patients and 31% for previously treated patients after approximately four years of follow-up. - The combination therapy achieved an objective response rate of 75% in treatment-naïve patients and 46% in previously treated patients with this rare lung cancer subtype. - These results potentially establish a new benchmark for targeted therapies in BRAF V600E-mutant metastatic NSCLC, a mutation found in approximately 2% of lung cancer cases.
